Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Migraine: Can Devices Spell Relief

Executive Summary

As many as half of severe migraine sufferers do not achieve adequate relief with prescription drug therapy, and many of these patients may be candidates for emerging device treatments for migraine. Sales of migraine drugs in the U.S. total more than $2 billion per year, but some analysts believe that the potential market for device-based treatment may be even larger. The question at the moment is whether the devices in development can produce the kind of results that migraine patients are looking for. Clinical trials are currently underway on a number of fronts, and based on early data, the answer looks promising.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel